Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104187 | 1.00 | SIGMAR1 (0.51) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| SCHEMBL104699 | 1.00 | SIGMAR1 (0.51) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL27966160 | 0.98 | SIGMAR1 (0.50) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| Dimethylamine SCHEMBL8560100 | 0.95 | SIGMAR1 (0.47) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| SCHEMBL15093677 | 0.91 | HRH3 (0.46) | SIGMAR1CYP2C19MAPTHRH2 | |
| Pyridine SCHEMBL28167226 | 0.90 | TP53 (0.44) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL2915951 | 0.88 | PDK1 (0.46) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 | |
| SCHEMBL17460241 | 0.87 | HTR1A (0.42) | SIGMAR1SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL19281788 | 0.87 | HTR1A (0.42) | SIGMAR1SLC6A2SLC6A4SLC6A3HTR2C | |
| Tert-Butyl Formate SCHEMBL27994114 | 0.85 | CYP2C19 (0.43) | SIGMAR1CYP2C19MAPTSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067625-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067625-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2022140643-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| WO-2013095275-A1 | NOVEL HEPATITIS C VIRUS INHIBITORS | MEDIVIR AB (SE) | 2013-06-27 | — | — | WO | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| US-7307081-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | SIGMAR1 1187/4885CYP2C19 1947/4885MAPT 2589/4885 |
| US-20240067625-A1 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | NR2E1, NR2E3, NR4A2 | SIGMAR1 812/4885CYP2C19 4706/4885MAPT 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.